Krystal Biotech, Inc. KRYS Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $417.3M+25.1% | $389.13M+33.9% | $373.16M+54.5% | $359.21M+116% | $333.45M+248% | ||
| $59.12M+3.9% | $58.05M+8.3% | $56.78M+10.4% | $55.71M+14.8% | $56.88M+26.1% | ||
| $155.2M+29.1% | $146.83M+29.2% | $136.67M+27.7% | $127.77M+25.2% | $120.23M+19.9% | ||
| $238.66M+6.2% | $227.93M+1.4% | $214.86M+0.4% | $219.8M+17.5% | $224.78M+37.5% | ||
| $238.66M+6.2% | $227.93M+1.4% | $214.86M+0.4% | $219.8M+17.5% | $224.78M+37.5% | ||
| $178.64M+64.4% | $161.2M+145% | $158.31M+550% | $139.41M+678% | $108.67M+254% | ||
| 42.8%+10.2pp | 41.4%+18.8pp | 42.4%+32.3pp | 38.8%+53.3pp | 32.6%+106pp | ||
| $28.68M-2.3% | $28.27M-4.6% | $28.64M+293% | $29.35M+336% | $29.36M— | ||
| $207.32M+50.2% | $189.47M+98.7% | $186.95M+226% | $168.75M+55.7% | $138.02M+133% | ||
| -$17.72M-226% | -$15.36M-348% | -$11.96M-338% | $22.03M+802% | $14.06M+616% | ||
| $225.03M+81.5% | $204.83M+130% | $198.91M+280% | $146.73M+38.5% | $123.96M+117% | ||
| 53.9%+16.7pp | 52.6%+21.9pp | 53.3%+31.6pp | 40.8%-22.9pp | 37.2%-22.4pp | ||
| $7.48+79.4% | $6.85+128% | $6.68+275% | $4.93+34.7% | $4.17+122% | ||
| $7.75+79.4% | $7.08+128% | $6.90+275% | $5.11+35.5% | $4.32+118% | ||
| 120M+0.7% | 119.4M+0.7% | 119.2M+2.2% | 119.3M+3.2% | 119.2M+5.8% | ||
| 116.1M+1.2% | 115.6M+1.2% | 115.3M+2.2% | 115M+2.6% | 114.7M+4.2% | ||
| $24.34M+7.4% | $23.05M+14.9% | $21.41M+19.0% | $23.83M+107% | $22.67M+311% | ||
| —— | $0+100% | -$9.38M+70.0% | -$18.75M+25.0% | -$28.13M-50.0% | ||
| $28.68M-2.3% | $28.27M-4.6% | $28.64M-3.9% | $29.35M+0.3% | $29.36M— | ||
| $223.02M+78.9% | $206.16M+133% | $198.5M+266% | $148.52M+40.7% | $124.65M+119% | ||
| $5.78M-1.5% | $5.67M-3.7% | $5.47M-9.5% | $5.37M-9.7% | $5.87M+9.8% | ||
| —— | —— | -$310K-117% | $873K+567% | $779K+4,682% | ||
| $417.3M+25.1% | $389.13M+33.9% | $373.16M+54.5% | $359.21M+116% | $333.45M+248% | ||
| $178.64M+64.4% | $161.2M+145% | $158.31M+550% | $139.41M+678% | $108.67M+254% | ||
| $184.42M+61.0% | $166.88M+133% | $163.78M+439% | $144.78M+881% | $114.54M+274% | ||
| $184.42M+61.0% | $166.88M+133% | $163.78M+439% | $144.78M+881% | $114.54M+274% | ||
| 44.2%+9.8pp | 42.9%+18.2pp | 43.9%+31.3pp | 40.3%+51.5pp | 34.3%+103pp | ||
| $178.64M+64.4% | $161.2M+145% | $158.31M+550% | $139.41M+678% | $108.67M+254% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Krystal Biotech, Inc.'s revenue?
- Krystal Biotech, Inc. (KRYS) generated $417.3M in revenue over the trailing twelve months, up 25.1% year over year.
- Is Krystal Biotech, Inc. profitable?
- Krystal Biotech, Inc. reported $225.0M in net income over the trailing twelve months, a 53.9% net margin.
- What is Krystal Biotech, Inc.'s earnings per share?
- Krystal Biotech, Inc.'s diluted EPS over the trailing twelve months is $7.48.
- Where does Krystal Biotech, Inc.'s income statement data come from?
- Every line is extracted from Krystal Biotech, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
